手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 国际临床医学 Volume 6, Issue 12. 2024.
免疫检查点抑制剂同步放疗治疗老年食管鳞癌患者的临床疗效及安全性分析
作者 : 刘 艳艳, 谢 富洋, 刘 俊香, 濮 娟*, 王 新
DOI: 10.18686/icm.v6i12.16683
全部来源
获取全文
摘要 / Abstract
目的：对比免疫检查点抑制剂 (immune checkpoint inhibitor,ICIs) 与放疗联合应用与传统放化疗在治疗老年食管鳞 癌方面的近期疗效和不良反应的差异。
关键词 / Keywords
老年食管鳞状细胞癌；免疫治疗；放射治疗
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1]Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics
  • 2020:GLOBOCAN estimates of incidence and mortality
  • worldwide for 36 cancers in 185 countries[J]. CA Cancer J
  • Clin,2021,71(3):209-249.
  • [2]Liu Q, Xia Y, Chen Y, et al. A study of concurrent
  • chemoradiotherapy with weekly docetaxel and cisplatin for
  • advanced esophageal squamous cell carcinoma with T4 and/or
  • M1 lymph node metastasis or locoregional recurrence [J].Radiat
  • Oncol,2020(15):75.
  • [3] 中国医师协会放射肿瘤治疗医师分会 , 中华医学会
  • 放射肿瘤治疗学分会 , 中国抗癌协会肿瘤放射治疗专业委员
  • 会 . 中国食管癌放射治疗指南 (2020 年版 )[J]. 国际肿瘤学杂
  • 志 ,2020,47(11):641-655.
  • [4]Kato K, Cho BC, Takahashi M, et al. Nivolumab versus
  • chemotherapy in patients with advanced oesophageal squamous
  • cell carcinoma refractory or intolerant to previous chemotherapy
  • (ATTRACTION-3): a multicentre, randomised, open-label, phase
  • 3 trial [J]. Lancet Oncol, 2019, 20:1506-1517.
  • [5]Huang J, Xu J, Chen Y, et al. Camrelizumab versus
  • investigator’s choice of chemotherapy as second-line therapy
  • for advanced or metastatic oesophageal squamous cell carcinoma
  • (ESCORT): a multicentre, randomised, open-label, phase 3 study
  • [J]. Lancet Oncol, 2020, 21:832-842.
  • [6]Shah MA, Kojima T, Hochhauser D, et al. Efficacy
  • and Safety of Pembrolizumab for Heavily Pretreated Patients
  • With Advanced, Metastatic Adenocarcinoma or Squamous Cell
  • Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
  • [J]. JAMA Oncol, 2019, 5:546-550.
  • [7] 张天 , 庞青松 . 局部晚期不可手术食管癌放射治疗研
  • 究进展 [J]. 中华肿瘤防治杂志 ,2023,30(3):174-180.
  • [8]Sun JM, Shen L, Shah MA, Enzinger P, et al.
  • Pembrolizumab plus chemotherapy versus chemotherapy
  • alone for first-line treatment of advanced oesophageal cancer
  • (KEYNOTE-590): a randomised, placebo-controlled, phase 3
  • study [J]. Lancet, 2021, 398:759-771.
  • [9]Janjigian YY, Shitara K, Moehler M, et al. First-line
  • nivolumab plus chemotherapy versus chemotherapy alone for
  • advanced gastric, gastro-oesophageal junction, and oesophageal
  • adenocarcinoma (CheckMate 649): a randomised, open-label,
  • phase 3 trial [J]. Lancet, 2021, 398:27-40.
  • [10]Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs
  • Placebo Added to Chemotherapy on Survival and Progression-
  • Free Survival in Patients With Advanced or Metastatic Esophageal
  • Squamous Cell Carcinoma: The ESCORT-1st Randomized
  • Clinical Tria [J]l. JAMA, 2021, 326:916-925.
  • [11]Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in
  • combination with chemotherapy as first line treatment for locally
  • advanced or metastatic oesophageal squamous cell carcinoma
  • (ORIENT-15): multicentre, randomised, double blind, phase 3
  • trial [J]. BMJ, 2022:e068714.
  • [12]Wang Z-X, Cui C, Yao J, et al. Toripalimab plus
  • chemotherapy in treatment-na ve, advanced esophageal squamous
  • cell carcinoma (JUPITER-06): A multi-center phase 3 trial [J].
  • Cancer Cell, 2022, 40:277-288.e273.
  • [13]Yang Y, Pan J, Wang H, et al. Tislelizumab
  • plus chemotherapy as first-line treatment for recurrent or
  • metastatic nasopharyngeal cancer: A multicenter phase 3 trial
  • (RATIONALE-309) [J]. Cancer Cell, 2023, 41:1061-1072.e1064.
  • [14]Zhu Y, Wen J, Li Q, et al. Toripalimab combined with
  • definitive chemoradiotherapy in locally advanced oesophageal
  • squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2
  • trial [J]. Lancet Oncol, 2023, 24:371-382.
  • [15]Conroy T, Galais MP, Raoul JL, et al. Definitive
  • chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin
  • in patients with oesophageal cancer (PRODIGE5/ACCORD17):
  • final results of a randomised, phase 2/3 trial [J]. Lancet Oncol,
  • 2014, 15:305-314.
  • [16]Zhang W, Yan C, Zhang T, et al. Addition of
  • camrelizumab to docetaxel, cisplatin, and radiation therapy
  • in patients with locally advanced esophageal squamous cell
  • carcinoma: a phase 1b study [J]. OncoImmunology, 2021, 10.
  • [17]Shen L, Kato K, Kim SB, et al. Tislelizumab Versus
  • Chemotherapy as Second-Line Treatment for Advanced or
  • Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-
  • 302):A Randomized Phase III Study [J]. J Clin Oncol, 2022,
  • 40:3065-3076.
  • [18] 陆 晓 , 陆 屸 , 金 振 军 等 . 信 迪 利 单 抗 联 合 化
  • 疗 治 疗 晚 期 胃 癌 的 疗 效 及 安 全 性 [J]. 临 床 药 物 治 疗 杂
  • 志 ,2023,21(11):47-51.
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号